High-Value Federal Grants ($5M+) — March 13, 2026

Five VA contracts totaling $1.65B underscore sustained demand for medical evaluations, IT/DevSecOps, and health insurance, with high outlays on some (e.g., $364M of $381M).

L3Harris ($814M NASA to 2029) and Lockheed ($65M DHS to 2026) secure multi-year engineering/services revenue, bolstering aerospace/defense stability.

$1.04B across three awards to 2029+ highlights biopharma R&D commitment, with small biz like MAPP ($185M obligated, $907M ceiling) showing growth.

Unobligated options exceed $2B across contracts (e.g., $453M Salient CRGT, $722M Cognosante), poised for exercise in IT/health.

Long performance periods (8+ years on $2.4B awards) and $0 outlays on top contracts (e.g., $820M TriWest, $814M BL Harbert) signal funding/execution delays.

Firm-fixed-price on 70%+ of value ($3.5B) exposes margins to cost overruns; full/open competition wins may face renewals pressure.

Heavy subawards (e.g., $168M L3Harris, $187M Salient) create supply chain dependencies amid potential labor/inflation pressures.

VA IT/health pipeline via repeat delivery orders; $1.65B awards to veteran-owned firms signal set-aside alignment.

Biodefense R&D escalation with $1B+ HHS/BARDA to 2032, favoring small biotech via options.

DHS/CBP IT set-asides for small/disadvantaged firms ($144M combined) offer entry into border/security tech.

10 of 15 contracts ($3.2B, 64%) target VA/HHS medical/IT/R&D, with 60%+ outlays on mature awards.

$1.0B in space/C4ISR to 2029+ reflects multi-year stability for primes.

Five awards ($435M) to veteran/8(a)/woman-owned firms via set-asides, despite $5B+ total.

{"entity"=>"TriWest Healthcare Alliance", "reason"=>"$820M VA award is largest; $0 outlay/1-month execution raises near-term flags.", "trigger"=>"Outlays >$100M or extension announcement"}

{"entity"=>"L3Harris Technologies", "reason"=>"$814M NASA to 2029 with $216M outlaid provides visibility; subawards key.", "trigger"=>"Q1 2026 option exercise or subaward delays"}

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"Small biz with $185M obligated/$907M ceiling in biodefense; high growth if options hit.", "trigger"=>"BARDA milestone payments or Phase III trial data"}

{"entity"=>"VA IT Sector (Cognosante/Technatomy)", "reason"=>"$376M combined with $240M+ options; DevSecOps demand rising.", "trigger"=>"FY2026 VA TAC NJ task order pipeline"}